132A
ASH XIV ABSTRACTS
AJH-APRIL
1999-VOL.
12, NO. 4, PART 2
DOS4
DO85
LERCANIDIPINE IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. C. Ascioti and G. Ferlaino (brd~olqy SWWC~ und (bronuty (bre Unrr. Hosprrul oj Lcrme:m ltrme (My) A&: to asses the efficacy and tolerance of Lercanidipine (L) (10 and 20 mgionce daily) in the treatment of mild to moderate essential hypertension; Materials ad Methods: 48 mild to moderate essential hypertensive Patients (Pt)(25 M, previous 23 F; mean age: 58+8.7), without any antihypertensive treatment were enrolled in the study after a 2 weeks placebo run-in period. Afterward, all Pt began a treatment with L (IO mg/once daily) for 4 weeks At the end of this period, all Pt whose Blood Pressure (BP) remained > 90mmHg were treated with L (20 mgionce daily) for a further 4 weeks period. Statistical analvsis: results are presented as means +SD. Student’s paired I test was used to compare Systolic (S) BP, Diastolic (D) BP and Heart Rate (HR) variations before and after treatment. m: L (10 mg/daily): 25/48 Pt (SZ.OS%) had a DBP<90 mmHg after 4 weeks of treatment. This percentage increased up to 3 1148 Pt (64.58%) with L (2Omg/daily). In particular, we obtained the following results: HR : SBP DBP 72+8.1 358k5.7 9856.6 Baseline 87+4.7** 73+7.4 147+5.4* L (IO mg) 88+4.2** 73+8.3 145+4.6** L (20 me)
a: Treatment with doxazosin in hypertensive patients with dyslipidemia in Primary Care Centers m: J.M.Celonio, R. Jimena, J.C. Ansede, A. Gil @i@& To assess the efficacy of doxamsin in hypertensive and
p
dyslipemic patients treated in Primary Care Centers. &k&n: Open, noncompamtivc multicentre study, we evalued the effects of doxamsin on blood oressure and lioid motile. These variables were messwed before and a&r the intervention, each patient behaves as his own contml. &&Q&S: 872 patients diagnosed of hypertension (Joint National Commitee and/or period
VI), and dyslipidemia,
triglycerides of 16 weeks.
5 2OOmg/dl) They received
(total
cholesteml
t
240 mg/dl
were shtdied for a maximun a daily dose of I up to 8 mg of
doxazosin raising the dose until blood pressure was controlled. Systolic and diastolic blood pressure and heart rate were r&&d at the baseline and in the 3”, 5”, P and 16”’ weeks. We also meassured total cholesterol, c-HDL, c-LDL, triglycerides, uric acid_
creatinine,glucose, and urea, before and tier our intervention. R@ai&: Doxazosin significantly reduced mean systolic and diastolic blood pressure by 23 (22.1-23.9) / 14.7 (14.1-15.2) mmHg, with no clinical effea on heart rate. Mean total cholesterol levels were significantly reduced by 14.8 % (13.7-15.8). lowdensity lipoprotein cholesterol levels by 14.6 % (12.9-16.3), and mean triglicexide levels by 19.6 % (17.1-22). High density lipopmteins cholesterol levels incresed by 9.3 % (7.8-11) (al1 p values < 0.05). The drug was well tolerated. Conclusions: This stody demonstrates that antihypxtensive therapy with doxamsin can favorably improve blood ~rossore levels and lipid profile.
** p’o.01;
The most important side-effects reported were: Ankle edema (2 Pt), Headache (I Pt), Flushing (I Pt). However, they were well-tollerated and none of Pt discontinued the treatment. Conclusions: L has demonstrated a very good efficacy and tolerance in the treatment of mild to moderate hypertension. ~~~ words: lercanidipine, hypertension.
Key Words:
DO86
DO87
BETA BLOCKER/HCTZ COMBINATION IS SUPERIOR TO BETA BLOCKER ALONE IN BLACK PATIENTS WITH MILD TO MODERATE HYPERTENSION I V Radevski’, Z P Valtchanova, G P Candy, E Tshele, P. Swell* Baragwanath Hospital, Johannesburg, South Atiwa. Low dose thiazlde diuretics and P-blockers are the most favored
QUINAPRIVHCTZ COMBINATION RATHER THAN LOW-DOSE BE RECOMMEND ED AS FIRST L[NE SHOULD HCTZ ANTIHYPERTENSIVE THERAPY IN BLACK PATIENTS WITH MILD TO MODERATE HYPER’IENSION. 1. V. Radevski’, Z. P Valtchanova, G P Candy, M Hopley, E Tshele, P Sareli*. Baragwanath Hospital, Johannesburg, South Afnca Low dose thiazide diuretics are recommended as first-hoe antthypertensive therapy m black patients with mdd to moderate addition to angiotensinconverting enzyme hypertension Moreover,
first line medications m black patxnts with mild to moderate hypertensmn They are often wmbmed to maximize blood pressure response. However, the role of P-blockers as first-hoe therapy in black patients 1s not well established In the present study we assessed the antIhypertensive e&acy of acebutolol 200 mg and carwdilol 25 mg od, given as a monotherapy for 3 months to 40 black patients (20 patients m each group, mean age 53klO years, 24 women) with mean day DBP >9OmmHg and lOmmHg) rates were achieved with both P-blockers after 3 months, most patwots requred combination therapy to achieve BP control at I2 months. At 12 months, patient remained controlled on acebutolol 2OOmg od and 2 patients remained controlled on cawedilol 25 mg The overall BP reduction at I2 months on combination therapy was profound and significant. ‘I&e control and response rates at 12 months were 59% and 82% for the acebutolol/HCTZ combo&on and 78% and 78% for the carveddolMCTZ combination, respectwely In both groups, a significant decrease in the 24 hour heart rate was observed In conclusion, p-blockers as monotherapy are less effectwe than combineboo of P-blocker/HCTZ and combmation therapy may be an appropriate fust hoe treatmeot to this population. mdd moderate hypertension, hypeltewon m blacks, Key Words:
I
to
acebutolol,
carved~lol, combination
therapy
Institution and location: Department of Preventive Medical School. Univenidad Complutense de Madrid.
Medicine
Hypertension, dyslipidemia, doxazosin.
m&bitors results in slgmticsnt blood pressure reduction In the present study we assessed the potential for BP control usmg low dose HCTZ (I2 5 mg od), gwen over I2 months to 49 black patients (mean age 54210 years, 27 women) with mean day DBP 290 mmHg and
mdd
to moderate
combination
therapy
hypertension,
hypertension
m blacks,